{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T07:48:44Z","timestamp":1794815324679,"version":"4.9.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Poverty"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The problem caused by viral hepatitis is a major public health challenge faced in the past decade, and the global goal of eliminating viral hepatitis by 2030 is still far away. With the use of hepatitis B vaccine and the launch of new drugs, there are more means to control viral hepatitis and more technologies to prevent, diagnose and treat it. While improving the coverage of vaccine use, drugs for treating hepatitis B are not only becoming more effective, but also decreasing in price. The objective of this article was to explore the urgent issues that need to be addressed in global viral hepatitis with the increasing availability of vaccines and antiviral drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main text<\/jats:title>\n            <jats:p>The updated World Health Organization guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection (2024 edition) and Chinese guidelines for the prevention and treatment of chronic hepatitis B (version 2022) simplify clinical algorithms for the diagnosis, treatment, and monitoring of hepatitis B, expand treatment eligibility criteria, and provide alternative treatment options, which will cover a higher proportion of all hepatitis B surface antigen positive populations. These actions promote the global goal of eliminating the public health hazards of viral hepatitis by 2030. Among the countries that have made remarkable progress in eliminating viral hepatitis policies, the key strategy is to simplify the diagnosis and treatment plan. Furthermore, the World Health Organization has identified 38 priority countries for viral hepatitis. Expand access to viral hepatitis services in these countries.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Regions and countries with the high burden of viral hepatitis still need to take urgent action regarding the new measures proposed by the WHO to achieve the 2030 targets. First, countries must establish a complete public health system aligned with the World Health Organization\u2019s strategy. Second, provide effective, people-oriented services and public prevention strategies. Third, prioritize the implementation of health strategies in the 38 identified priority countries. Finally, use complete and measurable data to monitor progress.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s40249-025-01275-y","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:11:47Z","timestamp":1738998707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Global progress, challenges and strategies in eliminating public threat of viral hepatitis"],"prefix":"10.1186","volume":"14","author":[{"given":"Sihui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"1275_CR1","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization, 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240091672."},{"issue":"4","key":"1275_CR2","first-page":"332","volume":"8","author":"FQ Cui","year":"2023","unstructured":"Cui FQ, Blach S, Mingiedi CM, Gonzalez MA, Alaama AS, Mozalevskis A, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol. 2023;8(4):332\u201342.","journal-title":"Lancet Gastroenterol"},{"key":"1275_CR3","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis. https:\/\/apps.who.int\/iris\/bitstream\/10665\/246177\/1\/WHO-HIV-2016.06-eng,pdf?ua=1."},{"key":"1275_CR4","unstructured":"World Health Organization. Global Hepatitis Report, 2017. http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/."},{"key":"1275_CR5","unstructured":"World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization, 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240090903."},{"issue":"6","key":"1275_CR6","first-page":"1425","volume":"11","author":"H You","year":"2023","unstructured":"You H, Wang FS, Li TS, Xu XY, Sun YM, Nan YM, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepato. 2023;11(6):1425\u201342.","journal-title":"J Clin Transl Hepato"},{"key":"1275_CR7","unstructured":"Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Zhonghua Gan Zang Bing Za Zhi. 2019;27(12):938\u201361 (In Chinese)."},{"key":"1275_CR8","first-page":"10073","volume":"35","author":"SH Zhang","year":"2023","unstructured":"Zhang SH, Wang C, Liu B, Lu QB, Shang J, Zhou YH, et al. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Reg Health West Pac. 2023;35:10073.","journal-title":"Lancet Reg Health West Pac"},{"issue":"3","key":"1275_CR9","doi-asserted-by":"publisher","first-page":"E791","DOI":"10.1093\/cid\/ciac385","volume":"76","author":"RJ Wong","year":"2023","unstructured":"Wong RJ, Kaufman HW, Niles JK, Kapoor H, Gish RG. Simplifying treatment criteria in chronic hepatitis B: reducing barriers to elimination. Clin Infect Dis. 2023;76(3):E791\u2013800.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1275_CR10","doi-asserted-by":"publisher","first-page":"E278","DOI":"10.1016\/S2214-109X(21)00517-9","volume":"10","author":"S Su","year":"2022","unstructured":"Su S, Wong WC, Zou ZR, Cheng DD, Ong JJ, Chan PL, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Glob Health. 2022;10(2):E278\u201387.","journal-title":"Lancet Glob Health"}],"container-title":["Infectious Diseases of Poverty"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-025-01275-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40249-025-01275-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40249-025-01275-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:11:57Z","timestamp":1738998717000},"score":1,"resource":{"primary":{"URL":"https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-025-01275-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1275"],"URL":"https:\/\/doi.org\/10.1186\/s40249-025-01275-y","relation":{},"ISSN":["2049-9957"],"issn-type":[{"value":"2049-9957","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}